John Vetto

Prof. John Vetto


Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JZJonathan S Zager
Jonathan S Zager
BGBrian R. Gastman
Brian R. Gastman
SLSancy A. Leachman
Sancy A. Leachman
RGRene C. Gonzalez
Rene C. Gonzalez
MFMartin D. Fleming
Martin D. Fleming
PGPedram Gerami
Pedram Gerami
The heterogeneous behavior of patients with melanoma makes prognostication challenging. To address this, a gene expression profile (GEP) test to predict metastatic risk was previously developed. This study evaluates the GEP’s prognostic accuracy in an independent cohort of cutaneous melanoma patients. This multi-center study analyzed primary melanoma tumors from 523 patients, using the GEP to classify patients as Class 1 (low risk) and Class 2 (high risk). Molecular classification was correlated to clinical outcome and assessed along with AJCC v7 staging criteria. Primary endpoints were recurrence-free (RFS) and distant metastasis-free (DMFS) survival. The 5-year RFS rates for Class 1 and Class 2 were 88% and 52%, respectively, and DMFS rates were 93% versus 60%, respectively (P < 0.001). The GEP was a significant predictor of RFS and DMFS in univariate analysis (hazard ratio [HR] = 5.4 and 6.6, respectively, P < 0.001 for each), along with Breslow thickness, ulceration, mitotic rate, and sentinel lymph node (SLN) status (P < 0.001 for each). GEP, tumor thickness and SLN status were significant predictors of RFS and DMFS in a multivariate model that also included ulceration and mitotic rate (RFS HR = 2.1, 1.2, and 2.5, respectively, P < 0.001 for each; and DMFS HR = 2.7, 1.3 and 3.0, respectively, P < 0.01 for each). The GEP test is an objective predictor of metastatic risk and provides additional independent prognostic information to traditional staging to help estimate an individual’s risk for recurrence. The assay identified 70% of stage I and II patients who ultimately developed distant metastasis. Its role in consideration of patients for adjuvant therapy should be examined prospectively.

29 January 2019 in Future Oncology
Verified
Journal Article
Open access
JVJohn Vetto
John Vetto
EHEddy C Hsueh
Eddy C Hsueh
BGBrian R Gastman
Brian R Gastman
LDLarry D Dillon
Larry D Dillon
FMFederico A Monzon
Federico A Monzon
MFMartin D Fleming
Martin D Fleming
Aim: Can gene expression profiling be used to identify patients with T1–T2 melanoma at low risk for sentinel lymph node (SLN) positivity? Patients & methods: Bioinformatics modeling determined a population in which a 31-gene expression profile test predicted <5% SLN positivity. Multicenter, prospectively-tested (n = 1421) and retrospective (n = 690) cohorts were used for validation and outcomes, respectively. Results: Patients 55–64 years and ≥65 years with a class 1A (low-risk) profile had SLN positivity rates of 4.9% and 1.6%. Class 2B (high-risk) patients had SLN positivity rates of 30.8% and 11.9%. Melanoma-specific survival was 99.3% for patients ≥55 years with class 1A, T1–T2 tumors and 55.0% for class 2B, SLN-positive, T1–T2 tumors. Conclusion: The 31-gene expression profile test identifies patients who could potentially avoid SLN biopsy.

1 May 2013 in The American Journal of Surgery
Verified
Journal Article
Closed access
JMJane K. Mills
Jane K. Mills
IWIan White
Ian White
BDBrian Diggs
Brian Diggs
JFJeanine Fortino
Jeanine Fortino
JVJohn Vetto
John Vetto

1 January 2002
Verified
Journal Article
Closed access
JPJohn K Petty
John K Petty
JVJohn Vetto
John Vetto
There is little solid evidence to support the belief that tumor conferences directly impact the care patients receive. This study investigated the recommendations made at tumor conferences and whether these recommendations were enacted. Cancer registrars from Oregon-area hospitals with tumor boards that utilized a prospective "working" format were surveyed regarding tumor board characteristics and content. They also recorded the recommendations made for each prospective case presented at each tumor board for one month. Later, they contacted each patient's provider to see which recommendations had been implemented. Information from eight tumor boards in six hospitals was recorded. The institutions varied with regard to size, location, number of tumor boards, number of cases reviewed annually, and types of cancers reviewed. One hundred fifty-three specific, prospective recommendations were made for the care of 97 patients. Of these, 128 (84%) were followed, 2 (1%) were pending, and 5 (3%) were status unknown. Of recommendations followed, 21 (16%) were for diagnosis, 100 (78%) were for therapy, and 7 (5%) were for palliation. Recommendations made at tumor conferences are generally implemented into patient care. Tumor boards can play a strategic role in the planning of care for cancer patients.

22 April 2019 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
DTDaniel C. Thomas
Daniel C. Thomas
GHGang Han
Gang Han
SLStanley Leong
Stanley Leong
MKMohammed Kashani-Sabet
Mohammed Kashani-Sabet
JVJohn Vetto
John Vetto
DHDale Han
Dale Han

31 May 2010 in The American Journal of Surgery
Verified
Journal Article
Closed access
AJAmariek J. Jensen
Amariek J. Jensen
ANArpana M. Naik
Arpana M. Naik
RPRodney F. Pommier
Rodney F. Pommier
JVJohn Vetto
John Vetto
MTMegan L. Troxell
Megan L. Troxell